Intercell Cuts Full-Year Sales, Earnings Forecast on Ixiaro

Intercell AG (ICLL) cut its forecast for full-year sales and earnings by as much as 20 percent, citing lower-than-expected demand for its Ixiaro vaccine against Japanese Encephalitis.

The net loss will be between 20 million euros ($26 million) and 24 million euros this year, the Vienna-based company said in statement today. Product sales will be between 26.5 million and 28.5 million euros, according to Intercell.

The company is scheduled to report third-quarter results on November 7.

To contact the reporter on this story: Eva von Schaper in Munich at evonschaper@bloomberg.net

To contact the editor responsible for this story: Phil Serafino at pserafino@bloomberg.net

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.